



AptarGroup Inc. (ATR)

Updated August 8th, 2025 by Felix Martinez

Key Metrics

Current Price:	\$140	5 Year Annual Expected Total Return:	4.6%	Market Cap:	\$9.1 B
Fair Value Price:	\$118	5 Year Growth Estimate:	7.0%	Ex-Dividend Date:	10/24/25
% Fair Value:	119%	5 Year Valuation Multiple Estimate:	-3.4%	Dividend Payment Date:	11/14/25
Dividend Yield:	1.3%	5 Year Price Target	\$165	Years Of Dividend Growth:	31
Dividend Risk Score:	B	Sector:	Materials	Rating:	Hold

Overview & Current Events

AptarGroup Inc. (ATR) began trading as an independent company in 1993 and is now one of the leading businesses in the global dispensing systems industry. With a market capitalization of approximately \$9.1 billion, The company has over 13,000 employees in 20 countries and produced \$3.6 billion in revenue in 2024. The company is divided into three business segments: "Beauty + Home," "Food + Beverage," and "Pharma."

The company reported second-quarter results for Fiscal Year (FY)2025 on August 1st, 2025. AptarGroup reported Q2 2025 revenue of \$966.0 million, up 6% from \$910.1 million in Q2 2024, with core sales up 3%. Reported net income rose 24% to \$112 million, and adjusted EBITDA increased 13% to \$218 million, achieving a 22.6% margin, up 140 basis points. Reported EPS grew 25% to \$1.67, and adjusted EPS rose 18% to \$1.66. Aptar Pharma led with 7% reported sales growth (3% core), driven by demand for proprietary drug delivery systems and higher-value elastomeric components for biologics and GLP-1, with a 35.4% adjusted EBITDA margin. Aptar Closures saw 8% reported sales growth (7% core), fueled by food and beverage demand, while Aptar Beauty grew 4% reported (1% core) with improved margins despite softer fragrance demand. For the first half of 2025, reported sales increased 2% to \$1.85 billion, with core sales also up 2%. Reported net income rose 10% to \$191 million, and adjusted EBITDA grew 8% to \$402 million. Reported EPS increased 10% to \$2.83, and adjusted EPS rose 8% to \$2.86. The company returned \$210 million to shareholders via dividends and \$140 million in share repurchases. The balance sheet showed total assets of \$4.87 billion, up from \$4.43 billion, with \$551.5 million in short-term debt and \$535.1 million in long-term debt. The effective tax rate dropped to 22.5% from 22.1%, aided by tax planning benefits.

For Q3 2025, Aptar projects adjusted EPS of \$1.53–\$1.61, factoring in 6–7 cents in legal fees for pharma IP litigation, with an effective tax rate of 20.5–22.5%. Pharma is expected to remain strong, driven by injectables, despite normalizing naloxone sales and elevated cough/cold inventory in Europe. Closures and Beauty should see modest contributions. With a focus on cost discipline and a robust pipeline, Aptar is well-positioned for sustained growth despite tariff uncertainties and supply chain challenges.

Growth on a Per-Share Basis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
EPS	\$3.00	\$3.13	\$3.40	\$4.00	\$3.95	\$3.64	\$3.88	\$3.79	\$4.78	\$5.64	\$5.88	\$8.25
DPS	\$1.14	\$1.22	\$1.28	\$1.32	\$1.42	\$1.44	\$1.50	\$1.52	\$1.58	\$1.72	\$1.80	\$2.19
Shares¹	62.5	62.2	61.9	62.9	66.0	67.0	67.7	66.7	66.9	67.7	68.0	65.0

AptarGroup's growth strategy encompasses both organic expansion and strategic acquisitions, with a noteworthy \$528 million investment in acquisitions during 2018, poised to fuel substantial future growth. While the company historically employed cash or debt for share buybacks resulting in a modest annual decrease in shares, recent years have shown an increase in total shares. The Pharma segment, constituting a third of sales but contributing two-thirds of EBITDA, stands out as the company's profit leader and primary growth driver, despite challenges posed by currency fluctuations and tax

¹ Share count is in millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



AptarGroup Inc. (ATR)

Updated August 8th, 2025 by Felix Martinez

changes. Anticipated are 7.0% annual earnings and 4.0% dividend growth over the next five years, reflecting a moderate slowdown from historical dividend growth rates of 4.7% over a decade and a 4.6% five-year dividend CAGR.

Valuation Analysis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
Avg. P/E	21.6	23.9	24.1	32.1	29.3	37.6	31.6	29.0	25.9	27.9	23.8	20.00
Avg. Yld.	1.7%	1.6%	1.6%	1.4%	1.2%	1.1%	1.2%	1.4%	1.3%	1.1%	1.3%	1.3%

AptarGroup currently trades for a valuation of over 23.8 earnings, which we consider rich for a company with low growth. The security looks fairly valued compared to its 10-year average of 28.3 times earnings. Additionally, the dividend yield is lower with its ten-year average of 1.4%.

From this point, there is more potential for a valuation reduction rather than valuation expansion over the next five years, in our view. We believe that a valuation of 20x earnings, modestly below its 10-year average, is fair given the company's adequate expected growth potential.

Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
Payout	38%	39%	38%	33%	36%	40%	39%	40%	33%	30%	31%	27%

AptarGroup has over 5,000 customers, with no customer accounting for more than 6% of sales. Additionally, three-quarters of sales come from outside the United States, with more than half of Europe's sales. The company has various patents and trademarks to protect its designs. However, it faces stiff competition and has historically achieved returns on invested capital marginally higher than its weighted average capital cost. However, the Pharma segment enjoys high switching costs due to regulatory certification and has higher profit margins.


AptarGroup has paid growing dividends for 30 consecutive years and maintains a low payout ratio. The company was only mildly affected by the previous recession, as it remained profitable and quickly recovered to all-time high sales and earnings in 2010. Its products across all three business segments are not very cyclical.

The company has nearly doubled its long-term debt over the past four years, but its interest coverage ratio remains healthy at over 8.6x. Also, the company has a debt-to-equity ratio of 0.5x which is really good. AptarGroup makes substantial use of leverage, although its consistent earnings should allow it to support that leverage safely.

Final Thoughts & Recommendation

In our view, AptarGroup is a durable company with a long history of growing dividends. However, the valuation is higher than its historical average and what we consider fair for this growth level. The company's sizeable foreign exposure is both a source of opportunity and a risk. We rate AptarGroup as a Hold now due to its low expected total returns of just -4.6% per year for the next five years.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



AptarGroup Inc. (ATR)

Updated August 8th, 2025 by Felix Martinez

Income Statement Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Revenue	2317	2331	2469	2765	2860	2929	3227	3322	3487	3583
Gross Profit	814	835	866	952	1041	1087	1157	1164	1263	1356
Gross Margin	35.2%	35.8%	35.1%	34.4%	36.4%	37.1%	35.8%	35.0%	36.2%	37.8%
SG&A Exp.	351	366	387	430	455	500	551	544	566	582
D&A Exp.	139	155	153	172	195	220	235	234	249	264
Operating Profit	324	314	326	350	392	366	371	386	449	510
Operating Margin	14.0%	13.5%	13.2%	12.7%	13.7%	12.5%	11.5%	11.6%	12.9%	14.2%
Net Profit	199	206	220	195	242	214	244	239	284	375
Net Margin	8.6%	8.8%	8.9%	7.0%	8.5%	7.3%	7.6%	7.2%	8.1%	10.5%
Free Cash Flow	174	194	168	102	267	318	56	163	257	349
Income Tax	95	75	75	71	100	87	78	95	91	96

Balance Sheet Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	2437	2607	3138	3378	3562	3990	4141	4203	4452	4432
Cash & Equivalents	490	466	713	262	242	300	123	142	224	224
Accounts Receivable	392	433	510	570	562	573	671	677	678	658
Inventories	295	297	337	381	376	379	441	487	513	462
Goodwill & Int. Ass.	342	502	539	967	1055	1243	1337	1261	1247	1191
Total Liabilities	1287	1433	1826	1955	1990	2139	2157	2135	2131	1946
Accounts Payable	115	116	154	165	193	244	285	320	329	296
Long-Term Debt	818	947	1257	1290	1196	1173	1193	1175	1139	1026
Shareholder's Equity	1149	1174	1312	1423	1572	1850	1969	2054	2307	2472
D/E Ratio	0.71	0.81	0.96	0.91	0.76	0.63	0.61	0.57	0.49	0.42

Profitability & Per Share Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Assets	8.2%	8.2%	7.7%	6.0%	7.0%	5.7%	6.0%	5.7%	6.6%	8.4%
Return on Equity	17.7%	17.7%	17.7%	14.2%	16.2%	12.5%	12.8%	11.9%	13.0%	15.6%
ROIC	10.2%	10.1%	9.4%	7.4%	8.8%	7.4%	7.9%	7.4%	8.5%	10.7%
Shares Out.	62.5	62.2	61.9	62.9	66.0	67.0	67.7	66.7	66.9	67.7
Revenue/Share	35.93	35.94	38.23	42.56	43.23	43.95	47.68	49.79	52.13	52.93
FCF/Share	2.70	2.99	2.60	1.57	4.04	4.77	0.82	2.44	3.84	5.16

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.